We are Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's lead solution platform is based on the Genio® system, a validated, user-centered, next generation neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
What is Obstructive Sleep Apnea
OSA and health risks
OSA is the most common sleep disordered breathing condition, affecting globally around 936 million people between 30 and 69 years of age, of whom 425 million suffer from moderate to severe OSA, requiring treatment*.
Left untreated, OSA is associated with increased mortality risk* and comorbidities, including cardiovascular diseases, depression and stroke.
Clinical studies have shown that the mortality rate of non-treated patients suffering from OSA increases significantly over time* . Untreated OSA is associated with a two-times more risk of stroke* and five-times more risk of cardiovascular mortality*. OSA increases the risk of heart failure by 140%*.